People · Operator
Named in public records as an officer, director or promoter · active 2024–2024 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Convergent Therapeutics, Inc. | — | Biotechnology | Series B | $51.4M | $153.1M | 2024 |
Jim Trenkle at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Jim Trenkle on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Jake Simson | 1 | 6 |
| Tal Zaks | 1 | 3 |
| Eric Sullivan | 1 | 3 |
| Alexander Brown | 1 | 3 |
| Philip Kantoff | 1 | 1 |
| Neil Bander | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.